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Clinical pain is a serious public health issue. Treatment of pain-related suffering requires knowl-
edge of howpain signals are initially interpreted and subsequently transmitted and perpetuated.
This review article is one of three reviews in this issue ofNeuron that address our understanding
of the pain process and possible solutions to the problem from both cellular- and systems-level
viewpoints.
Our understanding of the neural correlates of pain perception in humans has increased significantly
since the advent of neuroimaging. Relating neural activity changes to the varied pain experiences has
led to an increased awareness of how factors (e.g., cognition, emotion, context, injury) can separately
influence pain perception. Tying this body of knowledge in humans to work in animal models of pain
provides an opportunity to determine common features that reliably contribute to pain perception
and its modulation. One key system that underpins the ability to change pain intensity is the brain-
stem’s descending modulatory network with its pro- and antinociceptive components. We discuss
not only the latest data describing the cerebral signature of pain and its modulation in humans, but
also suggest that the brainstem plays a pivotal role in gating the degree of nociceptive transmission
so that the resultant pain experienced is appropriate for the particular situation of the individual.Pain as a Major Medical Health Problem
Pain that persists for more than three months is defined as
chronic and as such is one of largest medical health prob-
lems in the developed world. It affects approximately 20%
of the adult population, particularly women and the elderly
(Breivik et al., 2006).While themanagement and treatment
of acute pain is reasonably good, the needs of chronic
pain sufferers are largely unmet, creating an enormous
emotional and financial burden to sufferers, carers, and
society. Per annum, it is estimated that the cost of chronic
pain to Europe is E200 billion and to the USA over $150
billion. Improvements in our ability to diagnose chronic
pain and develop new treatments are desperately needed
but to achieve this we need robust and less subjective
‘‘readouts’’ of the pain experience.
Innovative methods, like molecular and systems neuro-
imaging, that can assess changes within the central ner-
vous system (CNS) of patients and relate these findings
to the wealth of information from animal studies, have
great potential and promise. Indeed, improvements in
our ability to identify the extent of changes within the
CNS, due to chronic pain, in animals and humans have
strengthened the case for considering chronic pain as
a disease in its own right. The mechanisms that contribute
to the generation and maintenance of a chronic pain stateare increasingly investigated and better understood. A
consequent shift in mindset that treats chronic pain as
a disease rather than a symptom is accelerating advances
in this field considerably.
Tying this new body of knowledge from patients and
normals with the extensive animal data on pain processing
in the CNS is timely. Common aspects regarding how pain
perception is mediated and modulated are being identi-
fied; this is the focus of our review.
Pain as a Perception
Pain is a conscious experience, an interpretation of the
nociceptive input influenced by memories, emotional,
pathological, genetic, and cognitive factors. Resultant
pain is not necessarily related linearly to the nociceptive
drive or input; neither is it solely for vital protective func-
tions. This is especially true in the chronic pain state. Fur-
thermore, the behavioral response by a subject to a painful
event is modified according to what is appropriate or pos-
sible in any particular situation. Pain is, therefore, a highly
subjective experience, as illustrated by the definition given
from the International Association for the Study of Pain
(Merksey and Bogduk, 1994): ‘‘an unpleasant sensory
and emotional experience associated with actual orNeuron 55, August 2, 2007 ª2007 Elsevier Inc. 377
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ReviewFigure 1. Schematic Illustrating theMain
Factors that Influence Nociceptive
Inputs to Affect Pain Perceptionpotential tissue damage, or described in terms of such
damage.’’
By its very nature, pain is therefore difficult to assess,
investigate, manage, and treat. Figure 1 illustrates the
mixture of factors that we know influence nociceptive
inputs to amplify, attenuate, and color the pain experi-
ence. We know also from more recent data how a painful
experience can occur without a primary nociceptive input
(Derbyshire et al., 2004; Eisenberger et al., 2003; Raij et al.,
2005; Singer et al., 2004), further complicating the story
but perhaps providing an alternative explanation for how
painmight arise in difficult clinical caseswhere the organic
cause is not obvious. What is clear is that many factors
influencing pain percepts are centrally mediated, and
our ability to unravel and neuroanatomically dissect their
contribution has only been feasible since neuroimaging
tools allowed us noninvasive access to the human CNS.
Determining the balance between peripheral versus
central influences and ascertaining which are due to path-
ological versus emotional or cognitive influences will
clearly aid decisions regarding the targeting of treatments
(i.e., pharmacological, surgical, cognitive behavioral or
physical rehabilitation). Understanding how complex
behavioral influences such as anxiety, depression, belief
states, and cognition change the pain experience in ani-
mals is difficult to assess due to the lack of sophisticated
behavioral paradigms and overdependence on threshold
or withdraw measures. However, a greater emphasis is
now being placed on measures of spontaneous pain
behaviors as well as on developing and utilizing animal
models of pain that more clearly mirror specific chronic
human pain conditions (Blackburn-Munro, 2004; Lindsay
et al., 2005; Schwei et al., 1999). Additionally, animal
pain models now routinely take into consideration the ge-
netic background, age, gender, and stress levels of the
animal as these have been shown to potentially have a sig-
nificant impact on the pain phenotype observed in animals378 Neuron 55, August 2, 2007 ª2007 Elsevier Inc.aswell as humans (Boccalon et al., 2006; Craft et al., 2004;
Mogil, 1999; Mogil et al., 1997, 2006). Indeed, a more inte-
grated approach for translating knowledge bidirectionally
between human and animal studies is already proving
beneficial, as recently demonstrated in the unexpected
identification of the potential central role of GTP cyclohy-
drolase (GCH1), the rate-limiting enzyme for tetrahydro-
biopterin (BH4) synthesis, as a keymodulator of peripheral
neuropathic and inflammatory pain in animal models and
humans suffering chronic pain (Tegeder et al., 2006).
Basic Neuroanatomy of Central Pain Processing
and the ‘‘Cerebral Signature’’ for Pain Perception
Beyond the peripheral nociceptor and dorsal horn, noci-
ceptive information ascends to the thalamus in the contra-
lateral spinothalamic tract (STT) and to the medulla and
brainstem via a spinoreticular (spinoparabrachial) and spi-
nomesencephalic tracts. These tracts serve different pur-
poses related to both their lamina origin in the dorsal horn
and final central destination (Dostrovsky and Craig, 2006).
Spinal projections to the brainstem are particularly impor-
tant for integrating nociceptive activity with homeostatic,
arousal, and autonomic processes, as well as providing
a means to indirectly convey nociceptive information to
forebrain regions after brainstem processing. The capac-
ity for projections to the brainstem to directly influence
both spinal and forebrain activity clearly suggest these
pathways play a direct role in affecting the pain experi-
ence; data from animals, healthy subjects, and patients
increasingly confirm the central role that the brainstem
plays in mediating changes in pain perception.
Functional and anatomical divisions of the thalamus, the
main relay site for nociceptive inputs to cortical and
subcortical structures, have been made on the basis of
their connections to specific spinal cord laminae in various
animal species and in humans (Craig, 2003b; Pralong
et al., 2004). Lamina I STT neurons largely project to the
Neuron
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ventral medial nucleus (VMpo), the ventral posterior infe-
rior nucleus (VPI), and the ventral caudal division of the
medial dorsal nucleus (MDvc). Recent evidence, however,
questions the lamina I STT projection to VP (Craig, 2006).
Lamina V STT axons terminate in VP, VPI, ventral lateral
nucleus, and intralaminar nuclei. However, the thalamus
and its connections spinally and supraspinally are still
debated in terms of nociceptive processing in humans.
Nevertheless, higher-resolution imaging studies coupled
to surgical investigations in humans have confirmed the
relevance of nuclei identified to date from animal studies
(Montes et al., 2005; Romanelli et al., 2004; Seghier
et al., 2005). As a critical relay site, it’s perhaps not surpris-
ing that the thalamus is implicated in chronic pain.
Decreased thalamic blood flow contralateral to the site
of pain in patients with cancer has been shown (Di Piero
et al., 1991), and in patients developing pain following
lesions to the peripheral or central nervous system, tha-
lamic hypoperfusion occurs. Of course, such hypoperfu-
sion could reflect either a decrease in neural activity or
deafferentation. A recent study of a patient with a left
medullary infarct (Wallenberg’s syndrome) attempted to
distinguish between these possibilities (Garcia-Larrea
et al., 2006). In this patient, extensive right-sided sensory
deficits were accompanied by left-sided facial pain, and
a PET scan revealed that the reduction of blood flow
occurred in the right thalamus, contralateral to the area
of pain. The repeat scan following pain relief afforded by
motor cortex stimulation showed restoration of thalamic
perfusion. This suggests that thalamic hypoperfusion
Figure 2. Neuroanatomy of Pain Processing
Main brain regions that activate during a painful experience, high-
lighted as bilaterally active but with increased activation on the contra-
lateral hemisphere (orange).indeed reflects the pain state, although it may not be path-
ophysiological per se. Future areas of investigation should
include targeted deep-brain stimulation in patients,
informed by white matter diffusion tractrography connec-
tivity maps, to better determine the role of specific
thalamic nuclei in pain perception and its modulation.
The Pain Matrix
Because pain is a complex, multifactorial subjective expe-
rience, a large distributed brain network is subsequently
accessed during nociceptive processing. Melzack (1999)
first described this as the pain ‘‘neuromatrix,’’ but it’s
now more commonly referred to as the ‘‘pain matrix’’;
simplistically it can be thought of as having lateral (sen-
sory-discriminatory) and medial (affective-cognitive-
evaluative) neuroanatomical components (Albe-Fessard
et al., 1985). However, because different brain regions
play amore or less active role depending upon the precise
interplay of the factors involved in influencing pain percep-
tion (e.g., cognition, mood, injury, and so forth), what
comprises the pain matrix is not unequivocally defined,
and the literature is not always consistent regarding
what regions are to be included. In our opinion, for the
pain matrix to retain its utility, it needs to be viewed not
as a stand-alone entity but rather as a substrate that is
significantly and actively modulated by a variety of brain
regions, and it is this interaction that in large part deter-
mines the pain experience.
A recent meta-analysis of human data from positron
emission tomography (PET), functional magnetic reso-
nance imaging (fMRI), electroencephalography (EEG),
and magnetoencephalography (MEG) studies does pro-
vide clarity regarding the commonest regions found active
during an acute pain experience (Apkarian et al., 2005).
These areas include: primary and secondary somatosen-
sory, insular, anterior cingulate, and prefrontal cortices as
well as the thalamus (Figure 2). That is not to say these
areas are the fundamental core network of human noci-
ceptive processing (and if ablated would cure all pain),
although recent studies investigating pharmacologically
induced analgesia do show predominant effects in these
brain regions (Casey et al., 2000; Geha et al., 2007; Rogers
et al., 2004; Wagner et al., 2007; Wise et al., 2002, 2004).
Other regions such as basal ganglia, cerebellum, amyg-
dala, hippocampus, and areas within the parietal and tem-
poral cortices can also be active dependent upon the
particular set of circumstances for that individual (Fig-
ure 2). Perhaps we need to move toward an individualized
neural ‘‘pain signature’’ rather than forcing this complex,
subjective experience into the constraints of a rigid neuro-
anatomical pain matrix (Tracey, 2005b). This is especially
true when considering the neural representation of
chronic, ongoing, or spontaneous pain in patients, some-
thing that has been studied only recently and appears to
not be represented necessarily by the conventional pain
matrix concept (Baliki et al., 2006). And of course data
showing activity of the near entire pain matrix without a
nociceptive input during hypnosis and empathy manipula-
tions support the notion it is time to reconsider how weNeuron 55, August 2, 2007 ª2007 Elsevier Inc. 379
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the input and resultant perception and meaning (Craig
et al., 1996; Derbyshire et al., 2004; Raij et al., 2005; Rain-
ville et al., 1997; Singer et al., 2004). That is not to say pain
experienced without a nociceptive input (sometimes re-
ferred to as psychogenic pain) is any less real than ‘‘phys-
ically’’ defined pain; indeed, neuroimaging studies have
highlighted the physiological reality of such experiences
due to the extensive neural activation that occurs. Rather,
it is to say we do not yet have a central signature that un-
equivocally reflects peripheral nociceptive inputs. Studies
using laser-evoked potentials (LEPs) and MEG that focus
more specifically on temporal aspects of nociceptive pro-
cessing, within spatially less well-defined brain regions,
provide signals reflecting the exogenous components
(i.e., fast direct nociceptive input represented by the oper-
culoinsula and/or S2 region) and endogenous compo-
nents (i.e., later integrated and convolved signal repre-
sented by the ACC) (Bentley et al., 2004; Garcia-Larrea
et al., 2003; Hobson et al., 2005; Iannetti et al., 2005a;
Ohara et al., 2004a). Great emphasis has, therefore,
been given to either the spatial or the temporal represen-
tation of nociceptive processing within functionally de-
fined brain regions, without consideration for how their
activation in concert causes a perception of pain. Pain
perception, similar to many complex experiences,
emerges from the flow and integration of information
among specific brain areas; greater emphasis on under-
standing temporal integration among these spatially de-
fined brain regions is needed and human multimodal im-
aging as well as animal studies may provide the solution.
In part, the focus on the rather simplified pain matrix is
a casualty of the intense focus and success pain re-
searchers have had in understanding molecular and cell
biology of primary afferent sensory neurons and their in-
teractions in the spinal cord (Julius and Basbaum, 2001;
Mantyh et al., 2002; Morris et al., 2004; Woolf and Salter,
2000). Over the past 20 years, this success has resulted in
a large scale ‘‘migration’’ of pain researchers studying the
involvement of higher centers of the brain (cerebral cortex,
thalamus, amygdala) to focusing on the sensory neuron
and spinal cord. However, with the advent and success
of noninvasive neuroimaging techniques in humans,
greater emphasis in animal experiments must be now
placed on how sensory neurons, the spinal cord, and
higher centers of the brain act in concert if we are to truly
begin to grasp how pain is perceived at a systems level.
Combining data from human imaging studies with neuro-
imaging, cellular, molecular, and behavioral studies in
animals has the potential to make similar progress in
understanding how higher centers of the brain are
involved pain perception as has been made in under-
standing the neurobiology of primary afferent nociceptors.
Interrelationship between Nociception and Pain
Perception: A Pivotal Role for the Brainstem
To understand at a system and molecular level how noci-
ceptive inputs are processed and altered to subsequently380 Neuron 55, August 2, 2007 ª2007 Elsevier Inc.influence changes in the pain experienced, it is useful to
separately examine the main factors known to alter pain
perception.
Cognition and Context
Attention
Anecdotal and experimental observations provide strong
evidence that attention is effective in modulating the sen-
sory and affective aspects of the pain experience (Levine
et al., 1982; Miron et al., 1989; Villemure and Bushnell,
2002). FMRI and neurophysiology studies show attention-
and distraction-related modulations of nociceptive-driven
activations in many parts of the brain’s pain processing
regions, with concomittant changes in perception (Bantick
et al., 2002; Legrain et al., 2002; Ohara et al., 2004b,
2004c; Petrovic et al., 2000; Peyron et al., 1999). However,
it is not known if a specific cerebral network dedicated
to the modulation of pain by attention exists and if so, if
it is different to the network that produces analgesia in
other circumstances (i.e., during placebo, acupuncture
[Napadow et al., 2007], or pharmacological manipulation).
One candidate network that might elicit pain modulation in
a generalized fashion is the descending pain modulatory
system; another network specific perhaps to attention
could further recruit other brain regions involved in pain
perception.
The Descending Pain Modulatory System
The descending pain modulatory system is a well-charac-
terized anatomical network that enables us to regulate
nociceptive processing (largely within the dorsal horn) in
various circumstances to produce either facilitation (pro-
nociception) or inhibition (antinociception) (Fields, 2005;
Hagbarth and Kerr, 1954). The pain-inhibiting circuitry, of
which the periaqueductal gray (PAG) is a part, is best
known and contributes to environmental (e.g., during the
fight-or-flight response) and opiate analgesia (Fields,
2005). There are descending pathways that facilitate
pain transmission, however, and it is thought that sus-
tained activation of these circuits may underlie some
states of chronic pain (see later; Gebhart, 2004; Porreca
et al., 2002; Suzuki et al., 2004). Knowledge regarding
this critically important system largely came from animal
studies. Early work repeatedly demonstrated that spinal
cord excitability was directly influenced by descending
inputs originating in higher centers of the brain and that
this descending modulation could be inhibitory and/or
facilitatory in nature (Basbaum and Fields, 1984; Porreca
et al., 2002; Ren and Dubner, 2002). The ability of higher
centers of the brain to modulate the transmission of noci-
ceptive information in the CNS was demonstrated in the
early 1900s by Sherrington who showed that nociceptive
reflexes were enhanced following spinal cord transection
(Sherrington, 1906). Over the last several decades, evi-
dence has accumulated that a variety of brain regions
are involved in this descendingmodulation and include the
frontal lobe, anterior cingulate cortex (ACC), insula, amyg-
dala, hypothalamus, PAG, nucleus cuneiformis (NCF), and
rostral ventromedial medulla (RVM). Figure 3 illustrates the
Neuron
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tory system.
More recently, researchers have investigated whether
alteration in people’s attention influences brainstem activ-
ity and, therefore, nociceptive processing via these corti-
cobrainstem influences. In an early study using high-
resolution imaging of the human brainstem, we showed
significantly increased activity within the PAG in subjects
who were distracted compared to when they paid atten-
tion to their pain, with concomitant changes in pain rat-
ings. Indeed, the change in pain rating between attending
and distracting conditions correlated with the change in
PAG activity across the group, suggesting a varying
capacity to engage the descending inhibitory system in
normal individuals (Tracey et al., 2002). Further work using
a counting stroop cognitive task attempted to identify the
cortical structures involved in mediating this brainstem
influence and subsequent change in pain matrix activity
to produce behavioral analgesia (Bantick et al., 2002).
Valet and coworkers extended the work further by using
connectivity analysis, an advanced method of analyzing
functional imaging, on FMRI data collected from controls
receiving nociceptive stimulation while performing a simi-
lar distraction/cognitive task. They showed that the cingu-
Figure 3. The Descending Pain Modulatory System
NCF (nucleus cuneiformis); PAG (periaqueductal gray); DLPT (dorso-
lateral pontine tegmentum); ACC (anterior cingulated cortex); +/ indi-
cates both pro- and anti- nociceptive influences, respectively.lofrontal cortex exerts top-down influences on the PAG
and posterior thalamus to gate pain modulation during
distraction (Valet et al., 2004). These studies provide clear
evidence for the involvement of brainstem structures in
the attentional modulation of pain perception, and recent
work using diffusion tractrography confirms that anatom-
ical connections exist between cortical and brainstem re-
gions in the human brain, thereby enabling such top-down
influences (Hadjipavlou et al., 2006). Adventurous studies
examining how biofeedback aids both a normal subject’s
or a chronic pain patient’s capacity to modulate their pain
experience, using real-time FMRI data analysis proce-
dures, provide novel ways to help us better understand
the cortical regions involved in the attentional control of
pain, enabling novel treatment options (deCharms et al.,
2005). A clinical feature of many chronic pain patients is
‘‘hypervigilance’’ to pain and pain-related information.
This has a direct impact not only on their resultant pain
perception but also quality of life if it impacts cognitive
performance. There are a number of explanations for
this attentional effect that are often the target for interven-
tions such as cognitive behavioral therapies (Crombez
et al., 2005). Clearly, recognizing the central role of the
brainstem in helping to mediate the analgesia and focus-
ing efforts to strengthen cortical connectivities to struc-
tures such as the PAG will be important in future work
and treatment developments.
Context
The commonest route to understand how context can
influence pain perception is via a placebo manipulation.
Much of our knowledge of the placebo effect has come
from early animal studies based upon Pavlovian condi-
tioning and expectancy (Benedetti et al., 2005; Haour,
2005). Recent work to translate these findings to humans
has helped provide a systems framework by which the
placebo effect and subsequent analgesia is mediated
(Colloca and Benedetti, 2005; Price et al., 2006, 2007).
Descending influences from the diencephalon, hypothala-
mus, amygdala, ACC, insular, and prefrontal cortex that
elicit inhibition or facilitation of nociceptive transmission
via brainstem structures are now thought to occur during
placebo analgesia. Using PET, Petrovic and colleagues
(2002) confirmed that both opioid and placebo analgesia
are associated with increased activity in the rostral ACC,
but they also observed a covariation between the activity
in the rostral ACC and the brainstem during both opioid
and placebo analgesia, but not during pain alone. Interest-
ingly, high responders to placebo mirrored their ability to
respond to real opioid injection compared to low placebo
responders, possibly reflecting a genetic influence in mu-
opioid receptors. Recently, Zubieta and colleagues (2005)
confirmed that placebo analgesic effects are mediated by
endogenous opioid activity on mu-opioid receptors using
a molecular imaging approach in humans. Wager and col-
leagues (2004) extended these observations to consider
whether or not placebo treatments produce analgesia by
altering expectations. Using a conditioning design, Wager
found that placebo analgesia was related to decreasedNeuron 55, August 2, 2007 ª2007 Elsevier Inc. 381
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(thalamus, insula, and ACC) but was additionally associ-
ated with increased activity during anticipation of pain in
the prefrontal cortex (PFC); an area involved inmaintaining
and updating internal representations of expectations.
Stronger PFC activation during anticipation of pain was
found to correlate with greater placebo-induced pain relief
and reductions in neural activity within pain regions.
Furthermore, placebo-increased activation of the PAG
region was found during anticipation, the activity within
which correlated significantly with dorsolateral PFC
(DLPFC) activity. These results support the concept that
prefrontal mechanisms can trigger opioid release within
the brainstem during expectancy to influence the de-
scending pain modulatory system and subsequently
modulate pain perception. In a very recent experiment
by Scott and colleagues, they examined the relationship
between placebo-related expectations and dopamine
release within the nucleus accumbens in humans using
molecular imaging. They found that activation of dopa-
mine release occurred during placebo administration
and that the extent of release was related to anticipated
effects as well as perception-anticipation mismatches
and subsequent placebo development. Furthermore,
using a reward task and fMRI, they found that expectancy
of monetary gain increased nucleus accumbens activity
proportionally to those measures obtained from the
molecular imaging study in the same subjects (Scott
et al., 2007). Studies such as these are significantly im-
proving our understanding of the placebo effect as well
as expectation of relief; areas of significant relevance for
assessing treatment outcomes in clinical trials.
Emotions and Mood
For both chronic and acute pain sufferers, mood and
emotional state has a significant impact on the resultant
pain perception and ability to cope. For example, it is
a common clinical and experimental observation that
anticipating and being anxious about pain can exacerbate
the pain experienced. Anticipating pain is highly adaptive;
we all learn in early life to avoid hot pans on stoves and not
to put your finger into a candle flame. However, for the
chronic pain patient it becomes maladaptive and can
lead to fear ofmovement, avoidance, anxiety, and so forth.
Many studies aimed at understanding how anticipation
and anxiety cause a heightened pain experience have
been performed over the past decade (Hsieh et al., 1999;
Ploghaus et al., 1999, 2000, 2001; Porro et al., 2002,
2003; Song et al., 2006). Critical regions involved in ampli-
fying or exacerbating the pain experience include the ento-
rhinal complex, amygdalae, anterior insula, and prefrontal
cortices. More recently, we have found that the degree of
anticipation to a pain event positively correlates with the
reported pain intensity across a group of healthy individ-
uals, and this amplification is mediated in part via activity
within the ventral tegmentum area of the brainstem and
entorhinal cortex, as well as the PAG (Fairhurst et al.,
2007). This data obtained in humans correlates well with382 Neuron 55, August 2, 2007 ª2007 Elsevier Inc.animal data in demonstrating that there is a clear interac-
tion between pain, anxiety, and mobility. While the body
of animal data is at times conflicting (anxiety can be pro-
or antinociceptive depending on the models used and
the endpoints assessed), what is clear is that the pain
response of the animal is emotion-specific, i.e., higher
centers of the brain in large part determine the behavioral
response to the same noxious stimulus. What is largely
lacking, however, is a cellular, molecular, and systems un-
derstanding of how distinct areas of the brain interact to
cause a heightened or diminished pain experience and
how prior ‘‘memories of pain’’ are stored so as to influence
current and future experiences of pain. Incorporating our
understanding of noradrenergic, serotonergic, opioidergic,
and now dopaminergic function in acute and chronic pain
processing from animal studies with the capacity to image
some of these neurotransmitters via molecular imaging in
humans and manipulate their levels with pharmacological
agents will lead to rapid advances in our understanding
of how complex moods influence pain experience.
Depressive disorders often accompany persistent pain.
Central neuronal plasticity may underlie both conditions,
further complicating our ability to dissect the components
contributing to clinical pain disorders (Castren, 2005).
Although the exact relationship between depression and
pain is unknown, with debate regarding whether one
condition leads to the other or if an underlying diathesis
exists, studies have attempted to isolate brain regions,
such as the amygdale, that may mediate their interaction
(Neugebauer et al., 2004). In another fMRI study, Giesecke
and colleagues (2005) showed that activation in amygdala
and anterior insula differentiated patients with fibromyal-
gia with and without major depression; however, more
studies that specifically address the interaction between
pain and depression are needed if we are to resolve the
neuroanatomical basis for the comorbidity.
Another negative cognitive and mood affect that
impacts pain is catastrophizing. This construct incorpo-
rates magnification of pain-related symptoms, rumination
about pain, feelings of helplessness, and pessimism about
pain-related outcomes (Edwards et al., 2006), and it is de-
fined as a set of negative emotional and cognitive pro-
cesses (Sullivan et al., 2001). A study on fibromyalgia pa-
tients found that pain catastrophizing, independent of the
influence of depression, was significantly associated with
increased activity in brain areas related to anticipation of
pain (medial frontal cortex, cerebellum), attention to pain
(dorsal ACC, dorsolateral prefrontal cortex), emotional as-
pects of pain (claustrum, closely connected to amygdala),
and motor control (Gracely et al., 2004). Clearly, these
results support the notion that catastrophizing influences
pain perception through altering attention and anticipa-
tion, as well as heightening emotional responses to pain.
It is interesting to speculate whether activity in such
‘‘emotional’’ brain regions due to chronic pain impacts
performance in tasks requiring emotional decision mak-
ing. Apkarian and colleagues (2004a) showed that during
the Iowa Gambling Task, a card game developed to study
Neuron
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played a specific cognitive deficit compared to controls,
suggesting such an impact might exist in everyday life.
Such experiments are hard to reproduce in animal studies;
however, if we are to understand what neural systemsme-
diate this potential disruption, more work is needed com-
bining these more complex paradigms with neuroimaging
techniques (Seymour et al., 2007).
Prefrontal, Frontal, and Insular Cortex
in Chronic Pain
It is clear from these few studies described and others in
the literature (Apkarian et al., 2001, 2005; Lorenz et al.,
2003; Phillips et al., 2003; Witting et al., 2006), that rostral
anterior insula and pronounced PFC activation are consis-
tently found across clinical pain conditions, irrespective of
underlying pathology. A recentmeta-analysis by Schwein-
hardt and colleagues (2006) highlighted that clinical pain is
located significantly more rostrally in the anterior insula
than nociceptive pain in healthy volunteers, consistent
perhaps with current theories regarding interoception
and body awareness (Craig, 2003a; Craig et al., 2000;
Critchley et al., 2004). Indeed, anterior insular activity is
found not only during subjective feelings of pain, but is
associated with anxiety, depression, irritable bowel syn-
drome, chronic fatigue, fibromyalgia, somatization, and
fear. Paulus and Stein (2006) have recently proposed
a role for the anterior insula in generating an altered inter-
oceptive prediction signal in individuals prone to anxiety.
In their model, an increased predictive signal of a prospec-
tive aversive body state (i.e., pain) triggers an increase in
anxiety, worried thoughts, and avoidance behaviors,
with possible pain amplification. This model certainly fits
with current data.
We are only beginning to unravel the roles of specific
prefrontal and frontal cortical regions in pain perception;
from other areas of cognitive neuroscience we can postu-
late roles reflecting emotional, cognitive, and interocep-
tive components of pain conditions, as well as perhaps
processing of negative emotions, response conflict, deci-
sion making, and appraisal of unfavorable personal out-
comes for more medial FC, ventrolateral, and medial
PFC (Dolan, 2002; Kalisch et al., 2006; Ridderinkhof
et al., 2004; Rushworth et al., 2004, 2005, 2007; Sakagami
and Pan, 2007). Baliki recently showed in chronic back
pain patients increased activity in mPFC, including rostral
ACC, during episodes of sustained high ongoing pain.
Furthermore, the medial PFC activity was strongly related
to the intensity of chronic back pain (Baliki et al., 2006). In
other pain studies, connectivity analyses of functional
imaging data have highlighted the relevance of frontal cor-
tical regions in mediating or controlling the functional
interactions among key nociceptive processing brain
regions to subsequently produce changes in perceptual
correlates of pain, independent of changes in nociceptive
inputs (Eisenberger et al., 2003; Lorenz et al., 2002;
Tracey, 2005a). A specific role for the lateral PFC as
a ‘‘pain control center’’ has been put forward in a study
of experimentally induced allodynia in healthy subjects(Lorenz et al., 2002). In this study, increased lateral PFC
activation was related to decreased pain affect, suppos-
edly by inhibiting the functional connectivity between
medial thalamus and midbrain, thereby driving endoge-
nous pain-inhibitory mechanisms. More recent studies
looking at control and pain support these concepts.Wiech
and colleagues manipulated the level of control healthy
subjects had over their pain and produced changes in
pain ratings dependent upon the control condition and
the subject’s internal locus of control. Using fMRI, they
showed that the analgesic effect of perceived control re-
lies on activation of right anterolateral PFC (Wiech et al.,
2006). It is perhaps important to note that the prefrontal
cortex (specifically the dorsolateral PFC) is a site of major
neurodegeneration and potential cell death in chronic pain
patients (Apkarian et al., 2004b). These unexpected find-
ings suggest that severe chronic pain could be considered
a neurodegenerative disorder that especially affects the
PFC. This could in turn have consequent negative effects
on the descending inhibitory system and contribute to
their chronic pain state.
There is no doubt that the extent to which a stimulus
(like pain) is identified as emotive and subsequently
produces and regulates an affective or emotive state is
dependent upon activity in many other regions such as
the amygdala, insular, ventral striatum, ACC, and hippo-
campus, as well as the PFC (Phillips et al., 2003). How-
ever, it remains to be determined whether emotional and
cognitive influences such as hypervigilance, catastrophiz-
ing, anxiety, or depression all mediate part of their recog-
nized influence on pain perception in chronic pain
sufferers via the descending pain modulatory system.
Recent advances in our ability to image activity within
the human brainstem (Dunckley et al., 2005; Tracey and
Iannetti, 2006) and map white matter tracts within the
human brain noninvasively using diffusion tensor imaging
and tractography (Behrens et al., 2003; Johansen-Berg
and Behrens, 2006; Le Bihan, 2003) are already contribut-
ing to a better understanding of the neuroanatomical con-
nectivity among different cortical, subcortical, and brain-
stem regions and, therefore, the likelihood of finding
a functional nociceptive link for these ‘‘top-down’’ influ-
ences (Hadjipavlou et al., 2006). It is known from animal
studies that the anterior insula is connected to brainstem
structures such as PAG, RVM, NCF, and parabrachial nu-
cleus (Fields, 2005); this provides a mechanism to partly
explain how emotions and mood might influence changes
in pain intensity perception. Additionally, as several of the
brainstem descending modulatory regions are either
ascending homeostatic integration sites or descending
autonomic premotor sites, it is perhaps feasible that a spe-
cific link exists between pain, homeostasis, and intero-
ception. Changes in the affective and cognitive state
might influence interoception to produce a bias in behav-
ior and decisions that affect outcome and pain perception.
Evidence is accumulating to support such concepts link-
ing homeostasis and pain; a recent study has provided
the first evidence that the vanilloid receptor, TRPV1 (aNeuron 55, August 2, 2007 ª2007 Elsevier Inc. 383
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producing stimuli like capsaicin, protons [pH < 5.7] and
heat) is also tonically activated in vivo and as such is
involved in body temperature regulation (Gavva et al.,
2007). Another study examinedwhether estradiol changes
in women influence pro- and antinociceptive mechanisms
(Smith et al., 2006). They found convincing estrogen-
associated variations in the activity of mu-opioid neuro-
transmission that correlated with individual ratings of the
sensory and affective perceptions of the pain, as well as
the subsequent recall of that experience. Molecular imag-
ing studies like these not only illustrate how systemic
biochemical changes influence behavior and perception,
but also provide novel opportunities to translate research
findings between animal models and humans.
Injury
Recently, changes within the descending pain modulatory
network have been implicated in chronic pain and in func-
tional pain disorders (Gebhart, 2004; Porreca et al., 2002;
Suzuki et al., 2004; Tracey and Dunckley, 2004). Changes
are defined in terms of patients having either a dysfunc-
tional descending inhibitory system or an activated and
enhanced descending facilitatory system. There has been
convincing evidence revealed regarding the differential in-
volvement of the PAG, RVM, parabrachial nucleus (PB),
dorsal reticular nucleus, and NCF in the generation and
maintenance of central sensitization states and hyperal-
gesia in both animal models and, for the first time in
humans, a humanmodel of secondary hyperalgesia (Zam-
breanu et al., 2005). This evidence has added to the
literature and the general notion that these structures
play an important role, in addition to the dorsal horn, in
generating and maintaining central sensitization.
Recent clinical studies are further highlighting how dys-
function within this system can be sufficient to generate
key symptoms of chronic pain. A study by Wilder-Smith
and colleagues (2004) investigated whether patients with
irritable bowel syndrome had hypersensitivity and pain
upon distension due to abnormalities in endogenous
pain inhibitory mechanisms; they found this to be the
case for patients compared with controls. In a study of
central post-stroke pain following an ischemic brainstem
injury, patients were found to experience pain in the
body side contralateral to their lesion. Furthermore, by
studying the patients using PET and a radiolabeled opioid
receptor agonist, Willoch and colleagues (2004) found
dramatic reductions in opioid-receptor binding in several
key nociceptive processing brain regions. These findings
suggest that an imbalance of excitatory and inhibitory
mechanisms contributes to either the generation or the
modulation of a pain experience both in patients and in
controls. Mayer and colleagues (2005) examined whether
visceral hypersensitivity found in patients with IBS might
arise as a consequence of aberrant top-down descending
influences. In a PET study, they observed greater activa-
tion of limbic and paralimbic circuits during rectal disten-
sion in patients with IBS compared with control subjects384 Neuron 55, August 2, 2007 ª2007 Elsevier Inc.or patients with quiescent ulcerative colitis. Functional
connectivity analysis suggested a failure to activate the
right lateral frontal cortex permits the inhibitory effects of
limbic and paralimbic circuits on PAG activation, the
consequence of which may be visceral hypersensitivity.
The same group recently examined the longitudinal
change in perceptual and brain activation response to vis-
ceral stimuli in IBS patients (Naliboff et al., 2006). Among
several changes, they noted a decreased brainstem activ-
ity to both the anticipation and experience of rectal infla-
tion after 12 months.
Changes within the descending pain modulatory net-
work in chronic pain, in terms of patients having either
a dysfunctional descending inhibitory system or an acti-
vated and enhanced descending facilitatory system, are
clearly implicated in these and increasingly other studies
(Edwards, 2005;Goadsby, 2007;Sandrini et al., 2006). Sei-
fert and Maihofner recently performed an fMRI study in
healthy subjects experiencing innocuous and noxious
cold as well as menthol-induced cold allodynia. Compar-
ing cold allodynia with equally intense cold pain condi-
tions, they show increased activations in bilateral dorsolat-
eral prefrontal cortices andbrainstemduring coldallodynia
(Seifert and Maihofner, 2007); reflecting the specificity of
brainstem activity for this chronic pain symptom. These
findings are supported by another study using the capsa-
icinmodel of hyperalgesia showing brainstem activity spe-
cific to secondary hyperalgesia (Mainero et al., 2007), re-
sults that fit with a clinical study showing differential
involvement of brainstem nuclei between affected and un-
affected sides in chronic neuropathic pain patients (Be-
cerra et al., 2006). Furthermore, recent pharmacological
studies are showing that gold-standard agents used to
treat key symptomsof neuropathicpainmediate their influ-
ence on brainstem structures (Iannetti et al., 2005b).
While activation of the descending inhibitory system is
generally viewed as desirable, it also has the potential to
mask a pain that would be useful in early diagnosis and
treatment of a disease (Mantyh, 2006). Recently, a trans-
genic mouse that spontaneously develops pancreatic
cancer was used to determine if the endogenous pain in-
hibitory system might be tonically active in masking early-
stage pancreatic cancer pain (Sevcik et al., 2006). These
mice, like humans with pancreatic cancer, usually only
display spontaneous morphine-reversible visceral pain-
related behaviors when the cancer is advanced, the tumor
has metastasized to vital organs, and effective treatment
or cure is no longer possible (Hawes et al., 2000). To test
whether CNS pathways might be masking early-stage
pancreatic cancer pain, mice that spontaneously develop
pancreatic cancer received subcutaneous administration
of the CNS penetrant opioid antagonists naloxone or
naltrexone. Following administration of these opioid an-
tagonists, mice with early pancreatic cancer, who before
demonstrated no spontaneous pain behaviors, now dis-
played a robust visceral pain-related behaviors. Further-
more, the endogenous opiates that tonically inhibit pan-
creatic cancer pain appear to exert their actions in the
Neuron
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penetrant opiate antagonist naloxone-methiodide did
not induce visceral pain behaviors in early stage-mice,
whereas intracerebroventricular injection of this same
compound increased visceral pain behaviors. These
data suggest that a CNS opiate-dependent mechanism
tonically masks early-stage pancreatic cancer pain (Sev-
cik et al., 2006). What is impressive about these results
is just how effectively the CNS can modulate pain. Once
pancreatic cancer pain appears, in both humans and
mice, it is frequently severe. This endogenous CNS inhibi-
tion of pain in pancreatic cancer is reminiscent of the
impressive analgesia that was originally demonstrated
by Reynolds in 1969, where it was shown that electrical
stimulation of rat PAG in awake moving rats allowed
abdominal surgery to be conducted without the use of
general anesthesia (Reynolds, 1969).
Together, these and other studies reinforce the concept
that CNS inhibitory or facilitatory mechanisms are remark-
able in their efficacy in being able to amplify or decrease
the pain experience (Vanegas and Schaible, 2004). There-
fore, understanding which CNS areas are involved in
engaging or disengaging this descendingmodulatory sys-
tem has significant potential to not only further our under-
standing of how pain is perceived, but also in developing
mechanism-based therapies for treating different types
of acute and chronic pain. Figure 4 summarizes our cur-
rent opinion regarding the central relevance of the brain-
stem and the descending modulatory system in affecting
the pain experienced in varying circumstances.
Molecular Imaging and Metabolic Changes:
Altered Opioidergic and Dopaminergic Pathways
The availability of PET ligands for opioid and dopamine re-
ceptors has allowed the study of these receptor systems
Figure 4. Current Hypothesis Regarding the Central Role of
the Descending Pain Modulatory System during Different
Pain Experiences
RVM (rostroventromedial medulla); PAG (periaqueductal gray); +/
indicates both pro- and anti- nociceptive influences, respectively.in several clinical pain states, providing yet further evi-
dence for an imbalance of excitatory and inhibitory mech-
anisms contributing to the generation or modulation of
pain in patients. Early opioid ligand studies (Jones et al.,
1994) showed decreased binding in patients with chronic
pain that normalized after reduction of their pain symp-
toms. Regional differences in ligand binding have also
been found in neuropathic pain studies (Jones et al.,
1999, 2004; Willoch et al., 2004) with decreased binding
in several key areas involved in pain perception. Future
studies, in particular longitudinal studies that correlate
binding potential with pain intensity, could help elucidate
whether decreased receptor availability is caused by
increased release of endogenous opioids or decreased
receptor density. A study of restless legs syndrome
showed that the opioid-binding potential is negatively cor-
related with the affective dimension of the McGill Pain
Questionnaire (von Spiczak et al., 2005), suggesting a
decrease of receptor density might be responsible for
the increase in pain affect.
The dopaminergic pathways have also been implicated
in pain processing in animal (Altier and Stewart, 1999;
Schmidt et al., 2002) and patient studies (Ertas et al.,
1998; Hagelberg et al., 2004; Taub, 1973). From certain
studies, it is hypothesized that the reduced activity may
mediate increased pain behavior found in animal models
of chronic stress (da Silva Torres et al., 2003; Scheggi
et al., 2002). A recent PET study in fibromyalgia patients
by Wood and colleagues showed reduced presynaptic
dopaminergic activity in several brain regions in which
dopamine plays a critical role in modulating nociceptive
processes (Wood et al., 2007), possibly highlighting dopa-
minergic dysregulation with functional pain disorders
where stress is a prominent aggravating factor (Wood,
2004). Similarly to the endogenous opioid system, the
issue of cause and effect between a ‘‘functional hypodo-
paminergic state’’ and pain has yet to be resolved. The
observation that reduced pain thresholds in patients with
Parkinson’s disease normalized, with corresponding
reductions in brain activation (insula and ACC), following
administration of levodopa suggests that attenuation of
dopaminergic activity underlies some chronic pain states
(Brefel-Courbon et al., 2005). However, the current data
from animal and patient studies on the role of dopamine
mechanisms in pain, using either dopamine agonists or
antagonists, are conflicting with regard to directionality
(i.e., pro- or antinociceptive responses upon dopamine
release) and location (i.e., nigrostriatal or mesolimbic
pathways). A study by Scott and colleagues (2006)
attempted to clarify this issue and showed that variations
in the human pain stress experience are mediated by ven-
tral and dorsal basal ganglia dopamine activity. Specifi-
cally, they found that activation of nigrostriatal dopamine
D2 receptor-mediated neurotransmission was positively
associated with individual variations in subjective ratings
of sensory and affective qualities of pain; contrasting
this, mesolimbic dopamine activation was only associated
with variations in the emotional responses of the individualNeuron 55, August 2, 2007 ª2007 Elsevier Inc. 385
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Reviewduring the pain challenge (i.e., increases in negative affect
and fear ratings).
Such molecular imaging studies are providing highly
novel information regarding pain processing in humans.
Although the data are not conclusive regarding causality,
it clearly shows that the brains of patients suffering chronic
pain are fundamentally disturbed in ways neither consid-
ered nor appreciated before. New avenues for exploration
and possible treatment targets are open, and this area is
becoming an active area of exploration.
Novel Areas of Investigation
As the problem of pain and the key role of the brain
becomes increasingly well recognized, more research is
being directed toward a better understanding of the un-
derlyingmechanisms. Some of the newest andmore novel
areas of investigation are briefly summarized here.
Structural Imaging
The recent finding that significant atrophy exists in the
brains of chronic pain patients (Apkarian et al., 2004b;
Grachev et al., 2000; Schmidt-Wilcke et al., 2005) high-
lights the need to performmore advanced structural imag-
ing measures and image analyses to quantify fully these
effects. Determining what the possible causal factors are
that produce such neurodegeneration is difficult. Candi-
dates include the chronic pain condition itself (i.e., excito-
toxic events due to barrage of nociceptive inputs), the
pharmacological agents prescribed, or perhaps the phys-
ical lifestyle change subsequent to becoming a chronic
pain patient. Carefully controlled longitudinal studies are
now needed as this rapidly becomes, along with diffusion
tractography studies to detect and quantify white matter
tracts, an active area of research. Such studies might
best be performed in animals.
Spinal Cord Imaging
Clearly, to determine the extent of changes present
within the CNS, we must develop methods that allow
noninvasive access to the changes within the human
spinal cord. There is an extensive literature from animal
studies regarding nociceptive processing within the dor-
sal horn to draw upon, and recent technical develop-
ments provide hope that translation to human studies
will be soon feasible (Brooks et al., 2006; Maieron
et al., 2007).
Imaging Microglial Activation
Recently, there has been considerable excitement over
the possible role that microglia play in the development
and maintenance of chronic pain states (Watkins et al.,
2001). To translate these exciting animal findings to
humans requires an ability to perform in vivo imaging of
the recruitment of microglial and macrophages into the
spinal cord and brain during the development of chronic
pain states. Ultrasmall, superparamagnetic particles of
iron oxide (or USPIO) are nanoparticles that might provide,
like the PET ligand PK11195, an indication of microglial
and macrophage recruitment (Bonnemain, 1998; Bulte
and Frank, 2000; Banati, 2002). Linking these studies to
those being currently performed provides an ideal oppor-386 Neuron 55, August 2, 2007 ª2007 Elsevier Inc.tunity to further explore the functional role of microglial in
developing chronic pain states.
Genetics
We cannot ignore the possibility that our genes influence
both how nociceptive stimuli are processed and how the
brain reacts to peripheral injury and increased nociceptive
inputs. Similarly, we cannot ignore the central role that our
life experiences have on both these processes. Coghill
and colleagues (2003) addressed the issue that some indi-
viduals claim to be ‘‘sensitive’’ to pain, whereas others
claim they tolerate pain well. In their experiment, individ-
uals who rated the pain highest exhibited more robust
pain-induced activation of S1, ACC, and PFC compared
with those who rated pain lowest. The key question is
whether this increased pain report and correlated objec-
tive readout is nature or nurture driven. The answer is
perhaps central to a better understanding of why certain
patients develop chronic pain syndromes and others do
not and perhaps explaining differences in treatment
outcomes. Similarly, if these observations are driven by
nurture, what influences in a person’s upbringing are rele-
vant for altering nociceptive pathways to again alter the
processing and resultant pain perception? Studies are
beginning to link genetic influences on human nociceptive
processing with physical processes within the brain.
Zubieta and colleagues (2003) examined the influence of
a common functional genetic polymorphism affecting
the metabolism of catecholamines on the modulation of
responses to sustained pain in humans using psycho-
physical assessment and PET. Individuals homozygous
for the met158 allele of the catechol-O-methyltransferase
polymorphism (val158 met) showed diminished regional
mu-opioid system responses to pain (measured using
PET) and higher sensory and affective ratings of pain com-
pared with heterozygotes. This provides clear evidence
that our genes influence nociceptive processing within
the brain and consequently our pain experience. The link
between our genes and pain perception during acute
and chronic pain experiences is one of the most exciting
areas of pain research at present and is being led primarily
by animal studies but with fast translation to human stud-
ies (Tegeder et al., 2006). Novel genes are being identified
that force us to reconsider pain mechanisms as they relate
to disease and perception. The hope is that this will lead to
novel treatments that provide better efficacy for patients.
Conclusion
We have attempted to summarize from a largely systems
neural-processing perspective the current state of knowl-
edge regarding how pain is perceived during varying
circumstances. We propose a central role for the brain-
stem and the descending pain modulatory system in af-
fecting the resultant pain experienced. Anatomical-, func-
tional-, molecular-, and tractography-based studies are
further elucidating connectivities between subcortical
and cortical structures to specific regions of the brain-
stem. This provides a framework for integrating nocicep-
tive inputs with top-down influences so that appropriate
Neuron
Reviewmodulation of these inputs, prior to higher-order process-
ing, is achieved to ensure the resultant pain experienced is
appropriate for that particular circumstance. In the chronic
pain state, we believe this integration is disrupted via
both bottom-up and top-down influences, contributing
to the generation and maintenance of a heightened pain
experience.
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